Cargando…

Noncardiac Versus Cardiac Mortality in Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction

BACKGROUND: A thorough analysis of noncardiac determinants of mortality in heart failure (HF) is missing. Furthermore, evidence conflicts on the outcome of patients with HF and no or mild systolic dysfunction. We aimed to investigate the prevalence of noncardiac and cardiac causes of death in a coho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vergaro, Giuseppe, Ghionzoli, Nicolò, Innocenti, Lisa, Taddei, Claudia, Giannoni, Alberto, Valleggi, Alessandro, Borrelli, Chiara, Senni, Michele, Passino, Claudio, Emdin, Michele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6818034/ https://www.ncbi.nlm.nih.gov/pubmed/31587602 http://dx.doi.org/10.1161/JAHA.119.013441

Ejemplares similares

Central and Obstructive Apneas in Heart Failure With Reduced, Mid-Range and Preserved Ejection Fraction
por: Borrelli, Chiara, et al.
Publicado: (2019)

Pathophysiological Rationale and Clinical Evidence for Neurohormonal Modulation in Heart Failure with Preserved Ejection Fraction
por: Castiglione, Vincenzo, et al.
Publicado: (2023)

Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin
por: Aimo, Alberto, et al.
Publicado: (2022)

Renin profiling predicts neurohormonal response to sacubitril/valsartan
por: Vergaro, Giuseppe, et al.
Publicado: (2020)

Novel Mechanisms in Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction
por: Lakhani, Ishan, et al.
Publicado: (2019)

The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction
por: Aimo, Alberto, et al.
Publicado: (2021)

Prognostic value of reverse remodelling criteria in heart failure with reduced or mid‐range ejection fraction
por: Aimo, Alberto, et al.
Publicado: (2021)

Heart Failure With Midrange Ejection Fraction: Prior Left Ventricular Ejection Fraction and Prognosis
por: Zhang, Xinxin, et al.
Publicado: (2021)

Prognostic Value of Cardiopulmonary Exercise Testing in Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction
por: Nadruz, Wilson, et al.
Publicado: (2017)

Mode of Death Among Japanese Adults With Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction
por: Kitai, Takeshi, et al.
Publicado: (2020)

Intact fibroblast growth factor 23 in heart failure with reduced and mildly reduced ejection fraction
por: Vergaro, Giuseppe, et al.
Publicado: (2023)

Differences in family caregiver experiences and expectations of end-of-life heart failure care across providers and settings: a systematic literature review
por: Valleggi, Alessandro, et al.
Publicado: (2023)

Central Apneas Are More Detrimental in Female Than in Male Patients With Heart Failure
por: Gentile, Francesco, et al.
Publicado: (2022)

Comorbidities, Fragility, and Quality of Life in Heart Failure Patients With Midrange Ejection Fraction
por: Gastelurrutia, Paloma, et al.
Publicado: (2018)

Heart Failure With Preserved Ejection Fraction: A Review of Cardiac and Noncardiac Pathophysiology
por: Gevaert, Andreas B., et al.
Publicado: (2019)

Type 2 Diabetes Mellitus and Chronic Heart Failure with Midrange and Preserved Ejection Fraction: A Focus on Serum Biomarkers of Fibrosis
por: Lebedev, D. A., et al.
Publicado: (2020)

Novel Drug Targets for Central Apneas in Heart Failure: On the Road
por: Borrelli, Chiara, et al.
Publicado: (2021)

Empagliflozin in heart failure with preserved ejection fraction: first success in mission impossible
por: Sciatti, Edoardo, et al.
Publicado: (2022)

Current and emerging drug targets in heart failure treatment
por: Ghionzoli, Nicolò, et al.
Publicado: (2021)

Cisplatin-induced cardiotoxicity with midrange ejection fraction: A case report and review of the literature
por: Hu, Yang, et al.
Publicado: (2018)

Clinical application of personalized medicine: heart failure with preserved left ventricular ejection fraction
por: Gori, Mauro, et al.
Publicado: (2020)

Biomarkers for the diagnosis and management of heart failure
por: Castiglione, Vincenzo, et al.
Publicado: (2021)

Contribution of the Lung to the Genesis of Cheyne‐Stokes Respiration in Heart Failure: Plant Gain Beyond Chemoreflex Gain and Circulation Time
por: Giannoni, Alberto, et al.
Publicado: (2019)

Subclinical cardiac damage in cancer patients before chemotherapy
por: Fabiani, Iacopo, et al.
Publicado: (2021)

Ventricular arrhythmias not meeting criteria for terminating cardiopulmonary exercise testing stratify prognosis and disease severity in heart failure of preserved, midrange, and reduced ejection fraction
por: Popovic, Dejana, et al.
Publicado: (2020)

Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: Rationale for and Practical Use of a Successful Therapy
por: Gori, Mauro, et al.
Publicado: (2022)

Value of the HFA‐PEFF and H(2)FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis
por: Tomasoni, Daniela, et al.
Publicado: (2022)

Efficacy and safety of sacubitril valsartan in treating heart failure with midrange ejection fraction after acute myocardial infarction in diabetic patients
por: Ye, Fanhao, et al.
Publicado: (2022)

Risk stratification in heart failure with mild reduced ejection fraction
por: Magrì, Damiano, et al.
Publicado: (2020)

Prediction of the Chemoreflex Gain by Common Clinical Variables in Heart Failure
por: Mirizzi, Gianluca, et al.
Publicado: (2016)

Left Ventricular Remodeling Risk Predicted by Two-Dimensional Speckle Tracking Echocardiography in Acute Myocardial Infarction Patients with Midrange or Preserved Ejection Fraction in Western Romania
por: Bordejevic, Diana Aurora, et al.
Publicado: (2021)

Haemodynamic validation of the three‐step HFA‐PEFF algorithm to diagnose heart failure with preserved ejection fraction
por: Lanzarone, Ettore, et al.
Publicado: (2023)

Racial differences of heart failure with midrange ejection fraction (HFmrEF): a large urban centre-based retrospective cohort study in the USA
por: Li, Dan Leslie, et al.
Publicado: (2019)

Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction
por: Butler, Javed, et al.
Publicado: (2022)

Prognostic Value of sST2 in Heart Failure
por: Sciatti, Edoardo, et al.
Publicado: (2023)

A Cross-Correlational Analysis between Electroencephalographic and End-Tidal Carbon Dioxide Signals: Methodological Issues in the Presence of Missing Data and Real Data Results
por: Morelli, Maria Sole, et al.
Publicado: (2016)

The ergoreflex: how the skeletal muscle modulates ventilation and cardiovascular function in health and disease
por: Aimo, Alberto, et al.
Publicado: (2021)

Surgical treatment of patients with aortic valve disease complicated with moderate functional mitral regurgitation and heart failure with midrange ejection fraction: a cohort study
por: Zhao, Wei, et al.
Publicado: (2022)

The Safety of The Directly Acting Antiviral Treatment For Hepatitis C Virus According To The Egyptian National Program Protocol In Patients With Midrange Ejection Fraction
por: Alaarag, Ahmed Farouk, et al.
Publicado: (2021)

Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions
por: Pugliese, Nicola Riccardo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n32lc73j48s5a01aulvkv0hdcs